Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
153 hedge funds and large institutions have $1.25B invested in Revance Therapeutics, Inc. in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 38 reducing their positions, and 13 closing their positions.
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
68% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 38
6% more funds holding
Funds holding: 144 → 153 (+9)
1% more capital invested
Capital invested by funds: $1.23B → $1.25B (+$11.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
35% less call options, than puts
Call options by funds: $6.79M | Put options by funds: $10.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.6M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$7.62M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.76M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.38M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$4.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$23.3M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$21.4M |
| 3 |
NCM
NovaQuest Capital Management
Raleigh,
North Carolina
|
-$10M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
-$5.51M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.09M |
RVNC Hedge Fund Activity: Q3 2020 in Review
153 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2020, worth a combined $1.25B — up 0.96% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RVNC positions and 13 closed out — a net gain of 9 holders — while 64 added to existing stakes and 38 trimmed.
The largest buyer was BlackRock, adding an estimated $11.6M. The largest seller was Franklin Resources, cutting an estimated $23.3M.
- 153 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2020, up from 144 in Q2 2020.
- Funds reported $1.25B of Revance Therapeutics, Inc. stock for Q3 2020, up 0.96% quarter-over-quarter.
- 22 funds opened new Revance Therapeutics, Inc. positions in Q3 2020 and 13 closed out, a net change of +9 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2020 was BlackRock, an estimated $11.6M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2020 was Franklin Resources, an estimated $23.3M sold.
Based on aggregated 13F filings for Q3 2020.